Chengdu Beite Denuo Pharmaceutical

Chengdu Beite Denuo Pharmaceutical is the dedicated innovative drug research and development subsidiary of the Chengdu Beite Pharmaceutical Group. Based in Chengdu, China, the company focuses on the discovery and clinical advancement of novel small molecule therapeutics, particularly in the fields of respiratory medicine, oncology, and anti-infectives. Its lead program, BT-1053, is a muscarinic receptor antagonist being developed for the treatment of chronic obstructive pulmonary disease (COPD). Beite Denuo integrates advanced medicinal chemistry and pharmacology platforms to transition the broader Beite Group from a traditional generic manufacturer to an innovation-led biopharmaceutical organization. The company benefits from the parent group's robust manufacturing capabilities and established commercial network within the Chinese healthcare market.